Speaker 1: Bloomberg Audio Studios podcasts, radio news, The.
Speaker 2: Stock Movers podcast, your roundup of companies making moves in
Speaker 2: the stock market harnessing the power of Bloomberg Data.
Speaker 3: Let's take a look at some of the stocks on
Speaker 3: the move today. AH Paul Sweeney alongside alex Steel Aren't
Speaker 3: turned by Bloomers denitza a COVID to what are you
Speaker 3: looking at today?
Speaker 1: Let's start with Quantum Computing. Obviously, that was one of
Speaker 1: the biggest winner of last year. The ticker is QUBT.
Speaker 1: Shares decline about nine percent after reaching an agreement with
Speaker 1: institutional investors for the purchase and sale of about fourteen
Speaker 1: million shares. This will be gross proceeds around two hundred
Speaker 1: million before expenses. That's a very interesting stock. Last year
Speaker 1: it was up seventeen hundred percent. Quantum Computing has obviously
Speaker 1: it's been a crazy it's been a really big buzz
Speaker 1: and among retail investors and others. There's so many metfs
Speaker 1: and a whole ecosystem around it. But the end of
Speaker 1: the year the company said it was awarded the contract
Speaker 1: with NASA. The whole technology of computing has incredible promise,
Speaker 1: processing power of millions time, greater than computers, which would
Speaker 1: be great for great drug discovery, material design, encryption, all that.
Speaker 1: The big issue is that it may take a very
Speaker 1: long time to do that. It's obviously a very expensive
Speaker 1: product process. So this year, the stock is not doing
Speaker 1: well at all after a crazy valley last year. Yeah,
Speaker 1: I mean that is I mean crazy rally is one
Speaker 1: hundred percent definition of that. Also, you're taking a look
Speaker 1: at visce Rep that is a fintech company that struck
Speaker 1: up over two percent. Uh yeah, we're looking at the
Speaker 1: Pfizer if they're launching their own stable coin and stable
Speaker 1: coins real heavy. Yeah, it's been, it's been in the
Speaker 1: news everywhere, and it's coming off legislation. Most surprisingly, I
Speaker 1: wouldn't think about the Senate passing a legislation on stable coins,
Speaker 1: but obviously that's slowly moving through Senate. Of course, it's
Speaker 1: part of the crypto industry supporting presents stromp reelection campaign
Speaker 1: and clearly a legislation coming there. Pfizer is up two
Speaker 1: percent today circle which we've been talking about a lot.
Speaker 1: It's of about fifteen percent. You can even keep track
Speaker 1: as the stock keeps rising. It's up seven hundred and
Speaker 1: ninety percent since it's ipol, this is a circle SRCL
Speaker 1: and Pfizer ticker Pfizerve ticker is FI. So those table
Speaker 1: coins give gain traction in traditional financial circles. With Wolemaker
Speaker 1: passing that legislation, stable coins are usually picked to the
Speaker 1: value of US of usset like the door. That's what
Speaker 1: the legislation offers. And yeah, they've been on a crazy
Speaker 1: run and everyone is wanting to get a piece of
Speaker 1: the pie. Paul, do we need our own stable coin?
Speaker 2: Now it's time? I think we do? We need? I need.
Speaker 3: I needed the IPL allocation at thirty one dollars a share.
Speaker 3: I don't know where that is. I don't see them account,
Speaker 3: so I'll call it all the people on the wall
Speaker 3: stream figure out what's happening. But that is thirty thirty
Speaker 3: one dollars I on June fourth this year, and look
Speaker 3: where we are just a couple of weeks later. Amazing.
Speaker 1: All right, one more, we have Excellence Tickeries e x
Speaker 1: e L. It's climbing after the company reported a positive
Speaker 1: top line results from a trail study on treatment for
Speaker 1: colorectal cancer. The stock is of about twelve percent and
Speaker 1: the year today gain is thirty six percent. Analysts are
Speaker 1: very optimistic. They said that the study is pretty much
Speaker 1: paving the way for the first regulatory approval of the treatment.
Speaker 1: The oncology company on Sunday said that it's in development
Speaker 1: cancer therapy demonstrated a significant improvement in survival rates for
Speaker 1: patients using the trick with a combination with another drug,
Speaker 1: so there is a lot of optimism among analysts. The
Speaker 1: company is having a strong year today gain and it's
Speaker 1: potentially moving to the next phase and getting very close
Speaker 1: to approval.
Speaker 2: The Stock Movers podcast from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.